Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study is an open label, multicenter, randomized phase II trial of consolidation
immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab
following concurrent chemoradiation in patients with unresectable stage III NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Greg Durm, MD
Collaborators:
Big Ten Cancer Research Consortium Bristol-Myers Squibb